OBJECTIVES: Surgical interventional has been key in the treatment of tuberculosis (TB) for a long time. Its importance diminished after the emergence of chemotherapy. However, the spread of rapid multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has led us to return to surgery to treat TB. Today, every second patient in Russia with destructive TB has either MDR or XDR TB, which is the reason for the low efficacy of conservative treatment. In 2015, treatment with drugs resulted in clinical recovery in only 29.8% of new cases of destructive TB acid-fast bacilli (AFB)+.
INTRODUCTION
Surgical treatment of tuberculosis (TB) has a long history. The first known surgery for TB was a cavernostomy performed in 1844 by Hasting and Storks [1] .
The main surgical methods used today were proposed more than a century ago. Such methods of treatment of TB were especially relevant during the preantitubercular period and during the period of limited application of chemotherapy. For instance, artificial pneumothorax combined with cautery destruction of pulmonary adhesions was performed in Russia in almost half of the patients who had destructive pulmonary TB from 1945 to 1947 and was efficient in 50-75% of cases, according to the data from the 1950s. [2] .
According to Stoiko [3] , a leading Russian TB surgeon of that period, the efficacy of extrapleural pneumolysis and extrapleural thoracoplasty reached 70-80% in the total absence or extremely limited application of anti-TB medication in Russia.
The widespread application of lung resections and thoracoplasties in the 1950s and 1960s, combined with the emergence of chemotherapy, allowed Western European and US medical practitioners to sanitize patients with TB. Consequently, surgical TB treatment has become almost unnecessary in economically developed countries.
In Russia, the work of such outstanding thoracic surgeons such as Drs Bogush, Naumov and Perelman [4] , who developed the School of Russian TB surgeons, was devoted to the popularization of surgical methods of TB treatment. However, it was not possible to eliminate TB as one of the most widespread diseases in Russia. The demand for TB surgeries in Russia is still significant, and, due to the growth in recent years of multidrugresistant (MDR) and extensively drug-resistant (XDR) TB, this demand has expanded. According to official statistics, every second registered patient in Russia has Mycobacterium tuberculosis with either MDR or XDR resistance. In terms of the spread of drug-resistant TB per 100 000 population, Russia, along with other former Soviet Union countries, sadly occupies the primary spot ( Fig. 1) [5] .
Consequently, the efficacy of treating destructive pulmonary TB in Russia is very low. According to official statistics, in 2014, the clinical recovery rate for first-time patients with bacterial excretion and a cavity of destruction in the pulmonary tissue was 29.8% [5] . Surgical techniques, which had rarely been applied in recent years (5% of recorded entries), made little impact on the recovery rate. At the same time, the application of surgical techniques in the treatment of patients with MDR and XDR TB, according to modern Russian and world literature, demonstrates good results with an efficacy of more than 90% [6] [7] [8] [9] [10] . However, the risks associated with surgical treatment were not sufficiently covered in the literature.
MATERIALS AND METHODS
The author's data for the period 1999-2016 have been analysed. The author performed 5599 surgeries on patients with pulmonary TB, aged 1-87 years (mean age 34.6 years). The most common reasons for surgical treatment were fibrotic cavitary and cavitary pulmonary TB-3274 (58.5%) (Fig. 2) ; tuberculoma with destruction-1051 (18.8%) patients (Fig. 3) ; tuberculous pleural empyema-1054 (18.8%) patients (Fig. 4) ; caseous pneumonia-190 (3.4%) cases (Fig. 5 ) and intrathoracic lymph node TB-30 (0.5%) (Fig. 6 ).
All patients in the preoperative and postoperative periods received antitubercular treatment. Although the duration of preoperative chemotherapy varied widely, in a majority of patients (84%), it ranged from 1 to 3 years. In accordance with Russian clinical recommendations, the indications for surgery and the terms of its application are defined by a commission consisting of a phthisis pulmonologist, a thoracic surgeon and an anaesthesiologist. The terms, usually ranging from 6 months to 2 years, and the protocols of postoperative chemotherapy are defined by the phthisis pulmonologist, taking into account the data from a bacteriological examination of the sputum and morphological and bacteriological examinations of the operating material and depend on the extent of TB activity, remaining focal changes in the lungs and the drug-resistant spectrum of the M. tuberculosis postoperative material.
With the preserved drug sensitivity of M. tuberculosis in the postoperative period, treatment with 4 first-line antitubercular drugs under the H (isoniazid), R (rifampicin), Z (pyrazinamide) and E (ethambutol) protocol was continued.
In cases of MDR TB, the treatment protocol consisted of at least 5 antitubercular drugs with mandatory inclusion of fluoroquinolones (levofloxacin, moxifloxacin or sparfloxacin) and aminoglycosides.
In cases of XDR TB, the antitubercular protocol consisted of at least 6 effective drugs and preferably included moxifloxacin, bedaquiline and linezolid.
In Russian methodical recommendations, which we adhered to, indications for pulmonary TB surgery are considered in connection with the clinical-anatomical forms of TB in the Russian classification system.
In intrathoracic lymph node TB in children, surgery was indicated no earlier than after 1 to 1.5 years of treatment in cases of large petrified mediastinal lymph nodes, especially with mediastinal compression, tuberculous intoxication and the presence of bronchonodular fistulas. The primary type of surgery in these instances was video-assisted thoracoscopic mediastinal lymphadenectomy. In certain instances, it was performed with resection of the bronchus in cases of stenotic changes and bronchonodular fistulas or with lung resection in cases of secondary changes in the pulmonary parenchyma.
In tuberculoma, surgery is indicated in cases of suspected malignancy, extensive size (> 2.5 cm) and destruction of tuberculoma, as well as multiple conglomerate tuberculomas; permanent bacterial excretion persisting despite prolonged adequate chemotherapy, especially if MDR TB or XDR TB is found; or tuberculoma exacerbating and progressing despite treatment and dynamic observation. For this form of TB, surgery is subsegmental or a segmental resection of the lung in the majority of cases and rarely, a lobectomy.
In cavitary pulmonary TB (if the cavern existed for up to 1 year and in the absence of gross fibrotic alteration in the lung), surgery is indicated after 4-12 months of treatment in the absence of a tendency for cavity closure as noted on a radiograph as well as persistent bacterial excretion under appropriate chemotherapy. An additional factor in favour of surgery for this as well as for other forms of TB is MDR or XDR M. tuberculosis. The most common type of surgery for cavitary TB is lobectomy and, rarely, segmental or polysegmental combined resection.
In the case of multiple foci in the remaining parts of the lung or in the contralateral lung, the recommended treatment is combined resection with 1-stage or postponed upper thoracoplasty with the resection of 3-4 ribs to prevent the reactivation of TB in the hyperextended lung. Rarely, there are indications for pneumonectomy in the case of polycavernous alterations in the lung. Original videoassisted thoracic surgery extrapleural upper-posterior thoracoplasty is able to stop cavitary TB with massive seeding progression and helps to close caverns when it is impossible to perform a resection.
In the case of fibrotic cavitary TB, if chronic caverns have existed for more than 1 year, a prominent fibrous capsule is present and there are gross sclerotic alterations in the surrounding tissue within a lobe or in the entire lung (combined with seeding), bacterial excretion persists in the majority of patients, over 90% of which excrete MDR or XDR M. tuberculosis. Surgery is contraindicated in most patients in this group due to extended bilateral invasion or low cardiorespiratory reserves. In patients in whom it is possible to operate (7.3% according to Russian statistics for 2014) [5] , pneumonectomy or thoracoplasty is commonly performed. Lobectomies and bilobectomies requiring 1-stage or postponed thoracoplasty because of heavy seeding are less common.
In caseous pneumonia (total caseous destruction of the lobe or the entire lung), surgical treatment is most often used in accordance with life-saving indications due to the steady, rapid progression of the process under treatment. The most common surgical procedure used in these cases is pneumonectomy. Rarely, it is possible to limit surgical invasion by performing a lobectomy or a bilobectomy. Collapse surgery in this group of patients as an independent type of surgical treatment is contraindicated; however, postponed thoracoplasty can be applied after resection to prevent postoperative complications and reactivation of TB.
Minimally invasive video-assisted thoracic surgery is applied in 65% of all surgeries, despite the regular presence of the adhesion process in the pleural cavity in patients with TB [11] .
To assess the long-term results of surgical treatment for TB, we analysed the data from one of the Russian regions where surgical treatment of newly identified patients with destructive pulmonary TB was widely applied, including by the authors of this article. In 2009, 334 patients with destructive pulmonary TB with bacterial excretion were identified in the Penza region. In the first year, various methods of surgical treatments were performed in 159 patients: artificial pneumothorax treatment was applied in 42 patients; artificial pneumoperitoneum was applied in 171 patients; in most patients, these methods were combined. We studied the results of these treatments after 3 years.
RESULTS
Surgical data from D.B. Giller demonstrated a 30-day mortality rate of 0.1%, and surgical complications requiring redo surgery comprised 1.9% of the population after a total of 5599 surgeries (Table 1) . A full clinical effect was achieved in 93% of patients with MDR TB who were operated on, in 92.1% of those with XDR TB and in 98% of patients without MDR or XDR resistance. A full clinical effect is defined as elimination of destructive, infiltrative alterations in the lungs, long-term cessation of bacterial excretion in sputum and absence of postoperative complications and of clinical manifestations of TB.
The degree of TB process activity had implications for immediate and long-term results. All deaths occurred in a group with acute TB progression at the time of surgery. Patients operated on for caseous pneumonia and fibrotic cavitary TB in the stage of rapid progression presented the greatest risk [12] .
According to an experimental procedure performed in the Penza region, direct treatment results of the entire group of 334 patients (destructive TB + bacterial excretion) in comparison with the treatment results of patients in the same category identified and treated in 2006-7, prior to the implementation of our proposed treatment strategy of early collapsotherapy and surgery, demonstrated a 2-fold increase in treatment efficacy and a 3-fold decrease in the number of deaths. Postoperative deaths were not observed, though the study of the results 3 years after treatment showed that 93.9% (149 of 159 cases) of patients had no TB relapse [13] . Treatment efficacy in the long term, which in Russia is estimated after 2-3 years of observation and defined by the index of clinical recovery, exceeded countrywide results by 2.8 times that for the experimental group of 334 patients (83.2% vs 29.3%).
DISCUSSION
Providing surgical care to patients with TB in a timely manner is paramount. Indications for surgery should be determined for all of the newly diagnosed patients during the first year of treatment. Our position on this issue is in line with the results of the study, which we coauthored, published by the World Health Organization (WHO) in 2014 [14] , where it is stated that 'surgery is an option in the treatment of TB patients with drug-susceptible M. tuberculosis and M/XDR-TB in localized cavitary forms with continuous M. tuberculosis excretion, confirmed by bacteriological examination and DST [drug-susceptibility testing], after four to six months of supervised anti-TB chemotherapy' (p. 12).
According to English written sources, surgical treatment in recent years has been applied mostly in patients with MDR TB (Table 2) . However, the rate of postoperative complications (from 0% to 39%) and the postoperative mortality rate (from 0% to 12.5%) varied significantly [7] [8] [9] [10] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Data on the efficacy of surgical treatment were also contradictory because some authors defined it as only the cessation of bacterial excretion, whereas others included radiographic and clinical data. However, in most publications, a positive outcome of surgical treatment was noted in more than 89% of cases, which is consistent with our data.
According to a meta-analysis conducted by Kempker et al. [30] , MDR TB chemotherapy results in patients receiving second-line antitubercular drugs in different studies varied significantly, but less than 10% of patients with MDR TB in the world received adequate treatment in accordance with international recommendations.
Taking into account the WHO data on the low level of therapeutic success in the treatment of MDR, especially XDR pulmonary TB, it is possible to conclude that, in regions with high levels of drug resistance, surgical treatment is still a necessary method capable of changing the situation for the better and sanitizing groups of epidemiologically dangerous patients.
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